Scipio bioscience, a Paris, France-based biotechnology company, raised €1.2m in seed funding.
Backers included Seventure Partners’ Quadrivium I seed fund and High-Tech Gründerfonds.
Led by Prof Stuart Edelstein, President, and Pierre Walrafen, Ph.D., CEO, Scipio bioscience leverages proprietary technology to provide a novel sample preparation solution for single-cell studies in the form of benchtop kits.
The company intends to use the funds to accelerate reinforcement of the R&D team focused on the completion of the first prototype kit, dedicated to single-cell transcriptomics.
Scipio bioscience plans to expand R&D operations into Germany in 2018.